Clinical Trials
Search our team at AdventHealth Research Institute
-
NCT06767514
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression (TPS greater than or equal to 50%)
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this research is to measure the safety and effectiveness of ivonescimab compared to pembrolizumab. Ivonescimab is an antibody designed to block proteins that help cancer cells grow and...
-
NCT06452277
A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations (SOHO-02)
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this study is to look at how well the new study drug works compared to standard medical care in participants with non-small cell lung cancer
-
NCT06745323
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer (SCLC) (DeLLphi-309)
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThis study is being done to learn more about tarlatamab in people with Small Cell Lung Cancer (SCLC; a type of fast-growing cancer that forms in tissues of the lung and can spread to other parts of...
-
NCT06667076
A Phase 2, Open-Label, Multi-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-based Chemo as Second-line Treatment, in Participants with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this study is to help researchers understand more about the possible effectiveness and safety of the combination of amivantamab and lazertinib in patients with non-small cell lung...
-
NCT05142696
A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this part of the study is to evaluate safety of Lutathera in patients with extensive stage small cell lung cancer (ES-SCLC) and to find the recommended dose of Lutathera in combination...
-
NCT06099639
Medical Access Program for Patritumab Deruxtecan (HER3-DXd, U3-1402)
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoIf a patient suffers from a life threatening or serious disease or condition where there is an unmet medical need that cannot be met by existing therapeutic options, and the patient is ineligible or...
-
NCT06203210
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician’s Choice (TPC) in Subjects with Relapsed Small Cell Lung Cancer (SCLC)
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoTo compare the efficacy of I-DXd with that of TPC, as measured by ORR per BICR and OS, in subjects with relapsed SCLC.
-
NCT06362252
A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-line Induction or Maintenance, in Subjects with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this study is to learn more about an investigational drug called Ifinatamab Deruxtecan or I-DXd. An investigational drug is a drug that is not approved for your disease. It is being...
-
NCT06008093
A Phase IIIb, Randomized, Multicenter, Open-label study, to assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination with Platinum Based Chemotherapy for First Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients who have Mutations or Co mutations in STK11, KEAP1, or KRAS (TRITON)
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoTo assess the efficacy of durvalumab plus tremelimumab plus chemotherapy compared with pembrolizumab plus chemotherapy in terms of OS, in participants with non-squamous histology who have metastatic...
-
NCT05671510
PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe main purpose of the study is to determine whether the study drug, ONC-392, is safe and well tolerated, and whether it is effective in treating lung cancer, in comparison with a standard of care...
-
NCT05498428
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe investigational anti-cancer drugs being studied are called amivantamab (JNJ-61186372) and lazertinib (JNJ-73841937). They are being developed for the treatment of locally advanced or metastatic (i...
-
NCT05211895
A Phase 3, Randomized, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab and Domvanalimab (AB154) as Sequential Therapy in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive, Platinum-based Concurrent Chemoradiation Therapy (PACIFIC 8)
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThis study is being carried out in stage III NSCLC which cannot be removed by surgery. In this study, we will identify the effectiveness and safety of a possible treatment combination – durvalumab...